Additional evidence shows that circZNF548, downregulated in NSCLC and associated with favorable prognosis, enhances CD8+ T-cell cytotoxicity via exosomal miR-7108-3p, while METTL14 reduces circZNF548 levels through m6A modification, thereby promoting tumor progression (Figure 2) (12). Here, CD8A is linked to neoplasm.